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ABSTRACT 
p53 tumour suppressor is a transcriptional factor which induces apoptosis or 
growth arrest in response to stress thus eliminating damaged cells. p53 function is 
frequently abrogated in tumours either via inactivation mutations in the TP53 gene or 
by elevated activity of p53 negative regulators HDM2 and HDMX. Therefore 
application of small molecules that reactivate p53 function is a promising strategy for 
anti-cancer therapy. In addition, small molecules can serve as valuable research tool to 
study p53 biology. 
This thesis is focused on the studies of p53 transcriptional response induced by 
small molecules and the molecular mechanisms contributing to the induction of 
apoptosis by p53. Using chromatin immunoprecipitation followed by deep sequencing 
(ChIP-seq) we compared genome-wide DNA binding profile of p53 activated by three 
different small molecules RITA, 5-FU and Nutlin-3a, causing various biological 
outcomes in breast carcinoma MCF7 cell line. We found that the major pattern of p53 
binding to DNA does not depend on the mechanism of p53 activation or p53-induced 
cell fate. Surprisingly, we demonstrated that the majority of sites bound by p53 are 
located far away from transcription starting sites (TSS), thus making unclear their 
functional role. Comparison of p53 DNA binding sites in vicinity to TSS with changes 
in gene expression using microarray analysis revealed 280 novel p53 target genes. 
While the majority of p53 transactivated genes shared classical p53 consensus motif, 
we found it only in a few repressed genes, suggesting different mechanism of p53 
transrepression. We validated several novel p53 target genes, including AURKA gene 
which is negatively regulated by p53. In addition, we showed that STAT3 transcription 
factor antagonizes p53-mediated regulation of several target genes, including AURKA. 
We demonstrated that the expression level of novel p53 target genes correlates with 
p53 status, tumour grade and survival in 265 breast cancer patients.  
Investigation of molecular mechanisms of p53-mediated apoptosis upon RITA 
treatment revealed that in addition to activation of pro-apoptotic targets, p53 inhibited 
the expression of several crucial oncogenes. Thus, we showed that inhibition of several 
oncogenic and pro-survival factors, including c-Myc and Mcl-1, on mRNA and protein 
levels critically contributes to robust induction of apoptosis. We found that in contrast 
to p53-mediated transactivation, transrepression is more tightly regulated by HDM2 
and depends on the ratio of p53 and HDM2 bound to gene promoters.  
We found that RITA-activated p53 mediates a decrease in expression and 
protein stability of its negative regulator HDMX. Impaired stability of HDMX is 
caused by ATM-mediated phosphorylation of HDMX. In turn, the elevated activity of 
ATM correlates with depletion of p53 target gene Wip1 phosphatase that inhibits ATM. 
We demonstrated that the depletion of either HDMX or Wip1 enhances growth 
suppressive effects of p53-reactivating molecules RITA and Nutlin3a. 
Our data showed that RITA inhibits glycolytic enzymes in p53-dependent 
manner. We found that p53 binds to DNA in vicinity from TSS of the metabolic genes 
and represses their transcription. Our data suggests that SP1 is a p53 transcriptional 
cofactor contributing to p53-mediated transrepression of several metabolic genes. 
Importantly, we showed that the block of glycolysis amplifies induction of apoptosis in 
cancer cells upon RITA treatment. 
In conclusion, our data contribute to a deeper understanding of transcriptional 
response induced by p53, along with the identification of novel p53 target genes. Our 
studies revealed new targets of pharmacologically activated p53 which significantly 
increase the robustness of p53-mediated apoptosis. 
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  1 
1 CANCER 
What is cancer? Cancer is one of the major causes of death across the globe; 
according to WHO it accounted for 7.6 million deaths (around 13% of all deaths) in 
2008 (IARC, 2011). 
Generally, cancer is characterised by excessive and uncontrolled proliferation of 
the cells, their immortality and the ability to metastasise into other tissues, to seed and 
grow there, and therefore affect the normal functions of the tissues. Hanahan and 
Weinberg proposed in their popular review “The hallmarks of cancer” that the 
transition of normal cells into cancer cells is a complex and multistep process of 
stepwise acquisition of six hallmarks of cancer: self-sufficiency in growth signals, 
unresponsiveness to anti-growth signals, evading apoptosis, limitless replicative 
potential, sustained angiogenesis, tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). In their recent review in 2011 Hanahan and Weinberg added four 
new hallmarks that enable cells to become carcinogenic and highly malignant, which 
are: deregulated cellular energetics, tumour-promoting inflammation, genome 
instability and, finally, escape from immune destruction (Hanahan and Weinberg, 
2011).  
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It is widely accepted that the cells obtain these features by gradual accumulation of 
alterations in DNA of somatic cells exposed to carcinogenic factors (Weinberg book, 
chapter 7). Both physical (X-rays or UV light) and chemical (aflatoxin, benzopyrene, 
ethidium bromide) carcinogens are able to induce mutations in a cellular genome 
(Figure 1). There are on average 50-100 mutated genes in tumour cells, but some of 
these mutations are not required for cancer development. These are called “passenger” 
mutations in contrast to “driver” mutations which are essential for cancer growth and 
survival (Frohling et al., 2007; Greenman et al., 2007). 
There are two different types of the genes that are absolutely crucial for tumour 
development: proto-oncogenes and tumour suppressors. Proto-oncogenes are 
precursors of oncogenes expressed in normal cells, which, due to mutations or elevated 
expression, gain growth-promoting or anti-apoptotic functions thus leading to 
hyperproliferation and cancer. Oncogenes can be divided into six functional groups: 
transcription factors (i.e. c-Myc, estrogene receptor), chromatin remodelers (ALL1), 
growth factors (PDGF), growth factor receptors (EGFR, PDGFR, VEGFR), signal 
transducers (SRC, Ras) and apoptosis regulators (Bcl-2, Bcl-xL) (Croce, 2008). At least 
a few of these genes are always found to be mutated in any type of cancer. Increased 
activity of oncogenes is essential, but usually not sufficient to induce a malignant 
tumour. A second event that has to occur during tumourigenesis is inactivation of 
another group of genes - the so called tumour suppressors. 
 
1.1 TUMOUR SUPPRESSOR FACTORS 
Tumour suppressors act to prevent the accumulation of mutations, restrict or 
suppress cell proliferation or to induce cell death. Abrogated function of tumour 
suppressors, either via loss of their expression or via mutations abolishing their activity, 
combined with oncogene activation leads to tumour development.  
The first identified tumour suppressor gene was the RB1 frequently altered in 
retinoblastoma. It encodes the retinoblastoma protein (pRb) that negatively regulates 
cell cycle progression through inactivation of E2F family of transcription factors. 
Discovery of the tumour suppressive activity of the pRb nicely illustrated the two-hit 
model proposing that in contrast to oncogenes where a mutation in only one allele is 
sufficient to stimulate oncogene activity, both alleles of the tumour suppressor gene 
have to be mutated to alter its function and induce cancer. At the same time it is now 
known that even partial loss of activity of a tumour suppressor can be crucial for 
promotion of cancer (Berger et al., 2011). Thus, deletion of only one allele of the 
tumour suppressor gene TP53 can contribute to tumourigenesis (Venkatachalam et al., 
1998). TP53 was discovered more then thirty years ago and is now one of the most 
intensively studied genes, as evidenced by more then 60,000 publications in the 
PubMed database up to date. Interestingly, it was originally thought to be an oncogene, 
until it was discovered that it was mutated in tumour cells which were used for its 
cloning (Eliyahu et al., 1988; Eliyahu et al., 1989; Eliyahu et al., 1984; Finlay et al., 
1988). 
 
1.2 P53 FAMILY OF TRANSCRIPTION FACTORS 
The p53 family of transcription factors consists of three members: p53, p63 and 
p73. All three members have a high similarity in DNA-binding domain and therefore 
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can bind similar DNA sequences and transactivate a similar group of genes. While both 
p63 and p73 might have a role in tumour suppression, they possess distinct functions 
(Collavin et al., 2010). Thus, p63 activity is essential for ectoderm development and 
prevention invasiveness and metastasis (Adorno et al., 2009; Levrero et al., 2000), 
whereas p73 plays a role in differentiation and neuronal development (Pozniak et al., 
2000). 
In the absence of stress p53 level and activity are kept low. The basal activity of 
p53 is sufficient to activate genes like TP53-inducible glycolysis and apoptosis 
regulator (TIGAR or C12orf5), sestrins 1 and 2 (SESN1, SESN2), glutathione 
peroxidises 1 and 2 (GPX1, GPX2), and aldehyde dehydrogenase-4 (ALDH4). These 
genes are involved in negative regulation of reactive oxygen species (ROS) and 
therefore can decrease the amount of DNA damage occurred spontaneously during 
proliferation of normal cells (Bensaad and Vousden, 2007). At the same time, exposure 
to a variety of genotoxic stresses (DNA damage, oncogene activation, hypoxia, 
nucleotide depletion) stabilizes and therefore activates p53 (Vousden and Lu, 2002). 
Depending on the severity of the stress and cell or tissue type p53 can induce cell cycle 
arrest, senescence, DNA repair or apoptosis (Figure 2). In other words, p53 acts as a 
sensor that can eliminate cells which carry irreversible DNA lesions or, if the damage is 
reparable, can promote DNA repair and survival of cells (Vousden and Prives, 2009).  
Implementation of the p53-mediated cell cycle arrest program is predominantly 
controlled through transcriptional activation of the inhibitor of cyclin-dependent 
kinases (CDKs) p21waf1, which induces both G1 and G2 arrest, whereas regulation of 
apoptotic function of p53 is more sophisticated and involve activation of pro-apoptotic 
genes (BAX, PMAIP1, BBC3), as well as repression of oncogenic factors (BCL2, 
BIRC5, MCL1, IGF1R).  
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p53 comprises 393 amino acid residues, which form six functional domains, that 
have important structural features for transcriptional regulation: 1: the N-terminal 
transactivation domain (NTD; including two transactivation subdomains: TAD1 
(residues 1-42) and TAD2 (residues 43-92), containing five proline-rich motifs 
(PXXP)), 2: the most conserved central (core, or DNA-binding domain; DBD, residues 
92-300) region, 3: a linker domain (residues 301-324; comprising nuclear localisation 
signal), 4: a tetramerization domain (residues 325-363) and 5: a C-terminal 
unstructured basic domain (residues 364-393; CTD) (Figure 5) (Mckinney and Prives, 
2002; Scoumanne et al., 2005).  
95.1% of point mutations occur in the DNA-binding domain of p53 suggesting 
that the sequence specific DNA binding of p53 plays a major role in its tumour 
suppressor function (Vousden and Lu, 2002). Although originally p53 was thought to 
act exclusively via regulating transcription, now it is known that p53 also mediates 
apoptosis in transcription–independent manner (Haupt et al., 1995), e.g. by binding to 
the anti-apoptotic proteins Bcl-xL and Bcl-2 and neutralizing their inhibitory effects 
against pro-apoptotic Bax and Bak proteins (Vaseva and Moll, 2009). Furthermore, 
upon an apoptotic stimulus p53 binds to Bax and Bak stimulating their ability to form 
homooligomers, leading to Cytochrome C release and caspase activation (Erster et al., 
2004; Mihara et al., 2003). 
Several factors influence the fine-tuned p53 transcriptional program upon various 
types of the stress. These comprise diverse post-translational modifications of p53, p53 
interaction with different partner proteins, and cooperation in cis between p53 and other 
transcriptional factors (Beckerman and Prives, 2010). In addition, p53 response 
elements (RE) have different affinity (see below for more details). All these features 
dynamically affect the complex stress-mediated p53 transcriptional response that 
eventually defines whether the cell will be subjected to apoptosis or to cell cycle arrest. 
 
1.3 THE MAJOR PRINCIPLES OF TRANSCRIPTIONAL REGULATION 
Transcription of genes in eukaryotic cells is regulated through the binding of 
proteins to regulatory DNA elements, such as promoters and enhancers (Lee and 
Young, 2000). Nearly one quarter of the eukaryotic genes contain TATA box in their 
promoters. A TATA box is a consensus sequence enriched with thymine and adenine 
that is important for binding of general transcription factors (GTF). Promoters also 
contain an initiator sequence (consensus motif that serves to recruit general 
transcription machinery, YYANWYY, where Y is a pyrimidine, W is either A or T 
(adenine or thymine) and N is any nucleotide) and additional binding sites for other 
transcription factors, that together recruit GTFs to the transcription starting site (TSS). 
GTFs are essential for the life of a cell as they initiate and coordinate the basal RNA 
polymerase II-mediated transcription; in the absence of binding of site-specific 
transcription factors to proximal promoters the level of transcription in a cell is low 
(Figure 3). Such transcription factors recognise specific DNA structures, defined by 
specific DNA sequences (so-called response elements) that determine the selectivity of 
these factors. In addition, transcriptional activity can be stimulated through the binding 
of site-specific transcription factors to enhancer regions. Notably, in some cases the 
binding of a transcription factors per se is not sufficient to strongly activate promoters 
but requires the presence of cell-type-specific factors that recruit coactivators and 
consequently activate transcription of the genes. Enhancers promote gene transcription 
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through the recruitment of chromatin remodelling factors that open chromatin and/or 
recruit kinases that stimulate the elongation of transcription. On the other hand, there 
are transcription repressors that bind to repressing sequences and attenuate the activity 
of transcription factors or recruit factors that form repressive conformation of 
chromatin.  
 
Thus, the fine-tuned regulation of gene transcription requires in most cases 
unique combinations of transcription activators and repressors (Farnham, 2009). 
Therefore, identification of transcription factor response elements and its protein 
coregulators are the primary aims in investigation of mechanisms of transcription 
mediated by site-specific transcription factors.  
 
1.4 THE MECHANISMS OF P53-MEDIATED TRANSCRIPTION 
1.4.1 Binding of p53 to DNA 
It is widely accepted that p53 recognises and binds with high-affinity to a 
consensus p53 RE, which contains two decameric half-sites 5'-RRRCWWGYYY-3' (R 
= purine; Y = pyrimidine; W = A or T) separated by a spacer (el-Deiry et al., 1992; 
Funk et al., 1992; Zauberman et al., 1993). p53 binds to DNA as a dimer of dimers, 
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where each p53 chain interacts with three nucleotides of the RRRCW or 
WGYYY quarter–sites. The spacer between the half-sites is 0-13 nucleotides, while 
some functional assays have proposed that a spacer <3 is optimal (Menendez et al., 
2009; Riley et al., 2008; Wei et al., 2006a). Although the canonical p53 binding site has 
been identified and experimentally validated, it has been found that nearly 95% of the 
validated direct p53 target genes have at least one mismatch. Furthermore, around 10% 
of confirmed targets have motifs that are not clearly related to consensus sequence 
(Menendez et al., 2009). For example, the PIG3 gene (p53-inducible gene 3) has a 
non-canonical binding site, containing a microsatellite response element (TGYCC)n 
(Contente et al., 2002) or the AQP3 gene has triplet pairs of pentameric p53 elements 
(Zheng and Chen, 2001).  
p53 REs can be found essentially anywhere within a target gene; a recent 
genome-wide studies show that a fraction of p53 binding sites can be found at relatively 
long distances from the 5’ and 3’ ends of a gene (more than 5 kbp) (Wei et al., 2006a). 
Although, the impact of such p53 sites on gene transcription remains unclear, the 
position of a response element relative to the TSS has a big impact on the strength of 
p53 transactivation and generally is lower for sites located at longer distance from the 
TSS. Thus, insertion of a 200 bp DNA fragment between the p53 binding site and the 
TATA box significantly attenuates the ability of p53 to activate transcription (Cook et 
al., 1995).  
In addition to the p53 binding sequence and its genomic location, several 
other features of p53 and local spatial structure of DNA influence the binding of p53 to 
the DNA sites. Thus, three p53 cystein residues, namely C176, C238, and C242 play an 
important role for DNA binding activity via coordination of a Zn++ ion (Hainaut and 
Milner, 1993) or/and changing p53’s redox status (Jayaraman et al., 1997; Seo et al., 
2002). Investigation of the mechanisms that are involved in recognition of RE by p53 
revealed that acetylation of CTD by p300/CBP acetyltransferase is capable to induce 
nonspecific binding to DNA (Avantaggiati et al., 1997; Gu and Roeder, 1997; Sang et 
al., 1997) but it is essential for in vivo occupation of p53 promoters (McKinney et al., 
2004). Interestingly, the DBD of p53 bends the DNA into a conformation that promotes 
the binding of the p53 tetramer (Balagurumoorthy et al., 1995; Nagaich et al., 1997a; 
Nagaich et al., 1997b).  
 
1.4.2 p53 regulates initiation and elongation of transcription 
As mentioned above, covalent modifications of histones which open chromatin 
structure for binding by GTF are often needed for initiation of transcription. 
Transactivation of p53 target genes upon DNA damage requires cooperation of several 
chromatin remodelling factors that methylate/acetylate histones in the vicinity of p53 
RE, e.g. histone methyltransferases PRMT1, CARM1 (An et al., 2004) and especially 
histone acetyltransferases (HATs) such as p300/CBP (Avantaggiati et al., 1997; Gu and 
Roeder, 1997; Scolnick et al., 1997), pCAF (Scolnick et al., 1997), GCN5 (Candau et 
al., 1997) and TIP60 (Gevry et al., 2007). Opening of DNA at p53 target promoters 
results in p53-mediated recruitment of several GTFs (TBP, TFIIA, TFIIH, and TAF1) 
to the TATA region, that allow initiation of transcription by RNA polymerase II (Ko 
and Prives, 1996; Li et al., 2007; Seto et al., 1992). In addition to initiation, p53 also 
controls elongation of transcription via its interaction with several elongation factors 
including Cdk9 (Claudio et al., 2006; Radhakrishnan and Gartel, 2006), FACT (Keller 
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and Lemberg, 2001), various components of the mediator complex (Gu et al., 1999) 
and ELL (Shinobu et al., 1999). 
 
1.4.3 Transcriptional repression by p53  
Apart from the transcriptional activation of the genes, p53 acts as a 
transrepressor (Ginsberg et al., 1991). While nearly 15% of p53 targets are known to be 
repressed by p53, it is still not clear whether their promoters share a consensus DNA 
motif defining p53 repression activity. It is possible that there are several different 
mechanisms of transcriptional repression by p53. For example, repression of AFP 
(alpha-fetoprotein), BCL2 (B-cell lymphoma-2) and HBV (hepatitis B virus) occurs 
due to p53 binding to REs which overlap with binding sites of other transcription 
factors, like FOXA1, POU4F1, RFX1, ABL1, thus competing them out (Budhram-
Mahadeo et al., 1999; Lee et al., 1999; Ori et al., 1998). On the other hand, CCNB1 
(Cyclin B1), TERT (telomerase reverse transcriptase), IGF1R (insulin-like growth 
factor 1 receptor), ALB (albumin) and MMP1 (matrix metallopeptidase-1) genes are 
repressed by p53 via sequestering and squelching the function of transcriptional 
activators SP1, CEBPβ and AP1 (Innocente and Lee, 2005; Kanaya et al., 2000; 
Kubicka et al., 1999; Sun et al., 2004). Yet, another mechanism of p53-mediated 
repression is the recruitment of histone deacetylase HDAC1 via interaction of p53 with 
the mSin3a/HDAC1 complex, which is important for the repression of MAP4 
(microtubule-associated protein-4), STMN1 (stathmin-1) and the HSP90AB1 (heat-
shock protein 90) genes (Murphy et al., 1999). p53-mediated transcriptional repression 
of some genes is indirect and occurs due to the activation of CDK inhibitor p21Waf1, 
which promotes pRb-mediated inhibition of transcription of the E2F-regulated genes 
(Lohr et al., 2003).  
 
1.4.4 Direct p53 target genes 
To date 162 direct p53 target genes that regulate various cellular processes 
(cell cycle arrest, apoptosis, transcription, metabolism, DNA repair) have been 
validated (Wang et al., 2009). The application of modern high-throughput methods 
such as ChIP-seq and ChIP-chip revealed a much longer list of possible targets. 
However, the validation of these new targets requires more thorough evaluation. Three 
major criteria have to be fulfilled in order for a gene to be accepted as p53 target: the 
presence of the p53 consensus binding site in the promoter, p53 binding to this site, 
location in the vicinity of the TSS, and differential gene expression upon p53 
activation. While this evaluation decreases the amount of false p53 target genes, it also 
has several serious drawbacks. It is hard to validate the target gene if it either does not 
have a canonical p53 RE or the RE is located at a significant distance from gene’s TSS. 
In the latter case the regulation might occur via DNA looping. In addition, the 
occupancy of the p53 binding sites may occur in cell-type-specific manner depending 
on chromatin organisation around the p53 RE (Lidor Nili et al., 2010). 
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1.5 PROMOTER SELECTIVITY DEFINES P53-MEDIATED 
TRANSCRIPTIONAL PROGRAM 
One of the major question that remains to be answered is how the differential 
induction of distinct transcriptional programs by p53 in response to different stimuli is 
achieved. Several factors could be involved in the regulation of a differential 
transcriptional response: the structure of p53 REs, p53 post-translational modifications, 
p53 binding partners, and the presence of other transcription factors in the vicinity of 
p53 binding sites. 
 
1.5.1 p53 response elements 
A variety of p53 binding sequences in the genome imply the existence of 
several DNA conformations of REs that certainly can affect the affinity of p53 to these 
sites. Indeed, computational and semi-in vitro studies (i.e., using p53 isolated from 
nuclear cell extracts exposed to REs attached to beads) show that p53 has a differential 
affinity to REs, depending on the sequence. The CATG sequence in the CWWG core 
especially favours p53 binding. But how do the differences in RE sequences influence 
the transactivation ability of p53? In vivo functional analysis, which allows to 
investigate the effect of a single nucleotide substitution in a consensus motif on 
transcriptional activity of p53, revealed that among all possible combinations within the 
CWWG decamer’s core the CATG motif is the strongest one in comparison with the 
other three (CAAG, CTAG or CTTG) (Jordan et al., 2008). Interestingly, the alignment 
of all experimentally validated p53 binding sites reveal that the CWWG motifs are the 
most conserved in p53 RE (Figure 4).  
Incorporation of a spacer and variations in the p53 decamer’s core nucleotides 
and adjacent nucleotides can also dramatically change the functionality of the RE. 
Interestingly, a comparison of several natural REs using a yeast functional assay with 
adjustable p53 level uncovered up to a 200-fold difference in the amount of p53 needed 
to transactivate reporters with inserted p53 RE. Thus, the CDKN1A gene (encoding 
p21Waf1, crucial for cell cycle arrest) has a strong RE (requires low level of p53), 
whereas BAX (Bcl-2 associated X) and PMAIP1 (NOXA, phorbol-12-myristate-13-
acetate-induced protein 1) (important for apoptosis) have weak ones (Jordan et al., 
2008). Probably the degeneracy of p53 RE in the promoters of weak genes makes their 
expression more dependent on the level of p53 and thus can provide precise fine-tuning 
which is very important for the genes deciding the fate of the cell. Thus, the level of 
p53 could be a decisive factor for activation of certain p53 regulated promoters that are 
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involved in different transcriptional programs. At the same time genome-wide studies 
have shown that in some cases the binding of p53 to its RE does not influence the 
activity of the promoter, suggesting that p53’s post-translation modifications or/and 
interaction with cofactors are needed to induce activation of these genes (Wei et al., 
2006a). 
 
1.5.2 Post-translational modifications  
Activity of p53 is regulated by various post-translational modifications that 
reflect activation of different cellular pathways (Bode and Dong, 2004; Sakaguchi et 
al., 1998; Tepel et al., 2004). A number of these modifications are involved in direct 
regulation of transcriptional activity of p53 (Figure 5). Thus, upon stress several 
kinases, like HIPK2 (D'Orazi et al., 2002), AMPK (Okoshi et al., 2008), PKC-δ 
(Yoshida et al., 2006), p38 (Perfettini et al., 2005) and DYRK-2 (Taira et al., 2007) 
phosphorylate p53 at S46 and promote selective activation of pro-apoptotic genes, e.g. 
the p53-regulated apoptosis-inducing protein 1 (AIP-1) (Oda et al., 2000). Interestingly, 
a recent genome-wide study also has shown that the decision to induce apoptosis is 
made by the DNA-bound fraction of S46-p53, but not S15-p53 (Smeenk et al., 2011). 
Furthermore, TIP60-mediated acetylation of p53 at K120 is required for activation of 
pro-apoptotic genes PMAIP1 and BAX (Sykes et al., 2006; Tang et al., 2006), while 
p300-mediated acetylation at K164 is needed for the expression of most p53 target 
genes (Tang et al., 2008). Interestingly, the cells containing p53 with constantly 
acetylated K382 are able to promote only cell cycle arrest, whereas cells expressing p53 
modified at K373 are also capable to induce apoptosis (Roy et al., 2005). In addition, 
arginine methylation at R333, R335, R337 (Jansson et al., 2008) and 
monoubiquitylation at K320 (Le Cam et al., 2006) can affect specifically p53-medited 
induction of cell-cycle arrest genes. 
Thus, the existence of such a complex and diverse code of post-translational 
modifications at least partially explains activation of various sets of p53 targets. 
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1.5.3 p53 binding cofactors 
Several cofactors have been shown to modify the transcriptional activity of p53 
(Figure 5). For example, the binding of two members of ASPP family proteins 
(apoptosis-stimulating protein of p53; ASPP1 and ASPP2) is crucial for the activation 
of pro-apoptotic genes such as PIG3 and BAX (Bergamaschi et al., 2004), whereas the 
third member iASPP binds p53 and antagonizes ASPP1/ASPP2- mediated induction of 
apoptotic targets (Bergamaschi et al., 2006). In addition, several other proteins such as 
Y-box binding protein YB1 (Homer et al., 2005), p52 subunit of NFκB (Schumm et al., 
2006) and p18/hamlet (Cuadrado et al., 2007; Lafarga et al., 2007) bind to p53 and 
promote a pro-apoptotic transcriptional program. On the other hand, p53 interaction 
with BRCA1 (MacLachlan et al., 2002), the membrane glycoprotein Muc1 (Wei et al., 
2006b) and zinc-finger protein Hzf (Das et al., 2007) cause preferential activation of 
cell cycle arrest genes. 
Furthermore, some p53 partners, like the E3 ubiquitin ligase HDM2, can affect 
p53 activity at distinct promoters, while no preference for modulation of expression of 
either pro- or anti-apoptotic genes has not been found (Minsky and Oren, 2004).  
 
1.5.4 Coregulation of p53 target genes by other transcription factors 
It should be noted that other master regulators could modulate the 
transcriptional regulation of some p53 targets genes. Thus, c-Myc in cooperation with 
its cofactor Miz is able to bind to the CDKN1A promoter, causing repression of the 
gene. However, such recruitment does not affect p53 binding to CDKN1A (Seoane et 
al., 2002). Additionally, a bioinformatics-based search for REs of other transcription 
factors revealed that Kruppel-like factor/paired box 4 (KLF/PAX4), SP1 and NFκB 
REs are enriched in vicinity of p53 binding sites (Smeenk et al., 2008), suggesting that 
these cofactors can participate in p53-mediated transcription.  
 
1.6 HDM2 AND HDMX ARE THE MAJOR NEGATIVE REGULATORS OF 
P53 
p53 plays a crucial role in activation of processes that affect the fate of a cell and 
therefore its activity has to be tightly regulated. 
Two RING (really interesting gene) finger proteins HDM2 and HDMX are the 
main negative regulators of p53’s level and activity in cells in the absence of stress 
(Haupt et al., 1997; Kubbutat et al., 1997). 
Indeed, several elegant mouse models have shown that the regulation of p53 
activity by MDM2 and MDM4 (mouse analogues of human HDM2 and HDMX) is 
absolutely vital during embryogenesis. Interestingly, knockout (Jones et al., 1995; 
Migliorini et al., 2002; Montes de Oca Luna et al., 1995; Parant et al., 2001) or 
conditional depletion (Francoz et al., 2006; Grier et al., 2006; Xiong et al., 2006) of 
either MDM2 or MDM4 during embryogenesis is embryonic lethal due to elevated 
activity of p53 which leads to massive apoptosis or growth arrest, respectively. The fact 
that p53 deletion in MDM2- or MDM4-null background can completely rescue 
embryonic lethality is a strong evidence of the crucial role of HDM2 or HDMX in 
controlling p53 function. Furthermore, even transient restoration of p53 is lethal for 
  11 
adult MDM2-null mice, while MDM4-null mice survive transient p53 restoration 
(Garcia et al., 2011; Ringshausen et al., 2006).  
Both HDM2 and HDMX have very similar structures and can interact with p53 
independently of each other, however only HDM2 holds E3 ligase activity, that 
polyubiquitinates p53, causing its proteasomal degradation (Marine and Lozano, 2010). 
Binding of HDMX to p53 in turn leads to transcriptional squelching of p53 activity 
(Marine et al., 2007; Marine and Jochemsen, 2005).  
Upon stressful conditions in normal cells the level of p53-complexes with HDM2 
and HDMX is decreased through ATM-mediated phosphorylation events that lead to 
ubiquitination and subsequent proteasomal degradation of HDM2/HDMX (Cheng et 
al., 2009; Khosravi et al., 1999; Maya et al., 2001; Pereg et al., 2005). This in turn 
results in p53 accumulation and activation and induction of p53 target genes (Cheng 
and Chen, 2010), including HDM2 thus forming a negative feedback loop (Barak et al., 
1994; Barak et al., 1993; Cheng and Chen, 2010; Wu et al., 1993). The wild-type p53 
induced phosphatase 1 (Wip1) is one of the p53 targets which is induced upon DNA 
damage. It is a functional antagonist of ATM that can dephosphorylate HDM2 and 
HDMX and therefore serve as an additional regulator of the p53/HDM2 negative 
feedback loop (Lu et al., 2007; Zhang et al., 2009). 
 
1.7 P53 CROSS-TALK WITH SIGNALLING PATHWAYS 
Activated p53 induces a global change in gene expression, although, as mentioned 
above, there are less than two hundred genes validated as direct p53 targets (Wang et 
al., 2001). This suggests that upon the differential expression of p53 targets, secondary 
effects on gene expression are unleashed. The ability to dramatically change gene 
expression makes p53 one of the key nodes of the cellular signalling which affects 
directly or indirectly a large number of cellular pathways. Interplay of p53 with 
IGF-1R/PI3K/Akt/mTOR and metabolic pathways has been investigated in my studies, 
and this is discussed below in details.  
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1.7.1 IGF-1R/PI3K/Akt pathway 
Insulin-like growth factor 1 receptor (IGF-1R) is a dimeric tyrosine kinase 
receptor, which is involved in cell proliferation and inhibition of apoptosis 
(Kurmasheva and Houghton, 2006). Each monomer of the receptor contains one 
extracellular α-subunit and one transmembrane β-subunit that carry tyrosine kinase 
activity (Adams et al., 2000; Ullrich et al., 1986). Activation of IGF-1R by its ligand 
IGF-1 leads to the dimerization of monomers and consequently phosphorylation of 
insulin receptor substrates (IRS-1 and IRS-4) resulting in recruitment of p110 subunit 
of phosphatidylinositol 3′ kinase (PI3K), the major transducer of the signals from 
IGF-1R. PI3K in turn activates Akt kinase that transmits the signal to several important 
downstream factors, including mammalian target of rapamycin (mTOR) kinase, 
glycogen synthase kinase β (GSK3β) and HDM2 (Figure 6).  
 Activation of mTOR by Akt-mediated phosphorylation at S2448 (Nave et al., 
1999; Sekulic et al., 2000) results in enhanced protein synthesis and proliferation due to 
the phosphorylation of S6K and inhibition of eukaryotic translation initiation factor 4E 
binding protein (4EBP1) (Brunn et al., 1997; Burnett et al., 1998). 
Phosphorylation of GSK3β by Akt on S9 leads to its inactivation as a kinase 
(Frame et al., 2001). GSK3β phosphorylates and therefore modulates activity of a 
number of transcription factors, signalling proteins and microtubules binding proteins 
(Kannoji et al., 2008) via different mechanisms. In particular, it phosphorylates several 
oncogenes and pro-survival factors, such as c-Myc, Cyclin E, β-catenin, Notch, c-Jun 
and Mcl-1 thus promoting their proteasomal degradation by F-box and WD repeat 
domain-containing 7 (FBW7) (Inuzuka et al., 2011; Mishra, 2010).  
Phosphorylation of HDM2 by Akt at S166 and S186 decreases its interaction 
with antagonist p14ARF and therefore promotes degradation of p53 (Gottlieb et al., 
2002; Zhou et al., 2001). Therefore activation of the IGF-1R/PI3K/Akt pathway not 
only promotes proliferation but also restrains p53.  
Interplay between the IGF-1R/Akt/mTOR pathway and p53 occurs also via 
other mechanisms. Thus, p53 induces the transcription of a negative regulator of PI3K 
PTEN (Stambolic et al., 2001) and at the same time represses several crucial members 
of this pathway, IGF1R (Webster et al., 1996; Werner et al., 1996), subunit of PI3K 
p110α (PIK3CA) (Astanehe et al., 2008), EIF4E (Zhu et al., 2005) and MYC (Ho et al., 
2005). In turn, GSK3β regulates the transcriptional activity of p53 by phosphorylating 
S33 of p53 (Buss et al., 2004). 
Deregulation of the components of IGF-1R/Akt/mTOR pathway is implicated in 
initiation of tumourigenesis (Cui, 2007) as well as in progression of various types of 
cancer (Belfiore, 2007). Furthermore, patients with high level of circulating IGF in 
blood have an increased risk to develop solid tumours in the future (Pollak et al., 2004). 
Essential role of this pathway in tumourigenesis along with tight interplay with p53 
makes its components an important targets for anti-cancer therapy (Chitnis et al., 2008). 
On the other hand, repression of IGF-1R/Akt/mTOR pathway upon the 
pharmacological activation of p53 might be an important feature of anti-cancer therapy 
based on p53 activation (Gottlieb et al., 2002).  
Indeed, recent studies reveal the “oncogene addiction”, i.e. dependency of the 
tumours on driving oncogenes. Thus, inhibition of oncogenes, like c-Myc, K-Ras, 
β-catenin, Cyclin E, or Cyclin D1 and others significantly decreases proliferation and 
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survival of the several types of tumour cells, as shown by recent studies on patient 
samples, mouse models and cell culture experiments (Weinstein and Joe, 2006). 
Therefore, inhibition of several oncogenes by pharmacologically activated p53 might 
be an important mechanism of eliminating cancer cells carrying different driving 
oncogenes. 
 
1.7.2 Metabolic pathways 
Uncontrolled proliferation of cancer cells requires increased amount of energy 
and therefore often, if not always, tumours are characterised by deregulated metabolic 
pathways, which is now defined as one of the hallmarks of cancer (Hanahan and 
Weinberg, 2011). Under aerobic conditions normal cells produce ATP, the main source 
of energy, via consequent processing of glucose to pyruvate (glycolysis in the cell 
cytoplasm) and finally to carbon dioxide (oxidative phosphorylation in mitochondria). 
At the same time, anaerobic conditions shift the energy production towards eighteen 
times less efficient glycolysis, since this process, in contrast to oxidative 
phosphorylation, does not require oxygen. Notably, cancer cells are characterized by 
the shift to glycolysis even in the presence of oxygen and such process was named 
Warburg effect or aerobic glycolysis (Warburg, 1956). 
The molecular basis of this paradox is partially due to the upregulation of glucose 
transporters, particularly GLUT1 that increases glucose uptake and compensates for the 
employment of inefficient glycolysis (Younes et al., 1996). At the same time, anaerobic 
glycolysis is also associated with oncogene activation, namely Ras and PI3K, along 
with hypoxia that occurs in many tumours. These two factors affect the level of HIF1α 
and HIF2α (hypoxia-inducible factor 1 and 2, α subunit) that are positive regulators of 
glucose uptake (DeBerardinis et al., 2008; Kroemer and Pouyssegur, 2008). Elevated 
levels of HIF1 transcription factor in turn promote the expression of several metabolic 
genes alone or in cooperation with c-Myc oncogene: SLC2A1 (GLUT1), HKII 
(hexokinase II), PDK1 (pyruvate dehydrogenase kinase 1), PFKM 
(phosphofructokinase, muscle) and LDHA (lactate dehydrogenase A) (Jones and 
Thompson, 2009; Kallio et al., 1997; Kim et al., 2006).  
Interestingly, mutant status of p53 is associated with the Warburg effect in 
tumour cells (Jones and Thompson, 2009). Moreover, cross-talk of aerobic glycolysis 
with p53 is proven and occurs mainly via p53-mediated transcriptional regulation of 
several genes involved in glycolysis and oxidative phosphorylation. Thus, p53 
transactivates TIGAR that redirects glycolysis to the penthose phosphate pathway 
(PPP) resulting in low ROS level and attenuated apoptosis (Bensaad et al., 2006). p53 
also increases transcription of the SCO2 gene (synthesis of cytochrome c oxidase 2), 
which is essential for oxidative phosphorylation induced by p53 (Matoba et al., 2006). 
Moreover, p53 decreases the expression level of PGM (phosphoglycerate mutase), a 
gene that enhances glycolysis (Kondoh et al., 2005). In addition to inhibition of 
glycolysis, p53 can directly decrease the glucose uptake by transrepression of SLC2A1 
and SLC2A4 (GLUT4) (Schwartzenberg-Bar-Yoseph et al., 2004).  
While it is clear that p53 negatively regulates glycolysis, the outcome of this 
inhibition is less clear and probably depends on the strength of p53 activation (Vousden 
and Ryan, 2009). At the same time, targeting the Warburg effect is a promising strategy 
to combat cancer and is under intensive investigation (Le et al., 2010; Scatena et al., 
2008).  
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1.8 TUMOUR METASTASIS 
More then 90% of all cancer-related mortalities occur due to metastatic spreading 
of tumours (Fidler, 2003; Hanahan and Weinberg, 2011). Moreover, in many cases the 
cancer is diagnosed at late stages when it is already metastatic. All this makes it 
important to understand the nature of metastasis formation, identification of biomarkers 
and the origins of metastasis in order to select a proper strategy to combat cancer, as 
well as to detect cancer at early stages, even before its propagation. 
The theory of metastasis formation was suggested more then a hundred years ago 
by Steven Paget and termed “seed and soil” hypothesis (Paget, 1989). Tumour cells are 
compared with seeds that are constantly distributed from the primary tumours, 
searching for the appropriate cell environment (soil) to establish secondary tumours 
(metastasis). Understanding of the general concept of cancer development requires 
identification of the features that define metastatic phenotype of the cells. Proper 
understanding of the genotype of metastatic cells will offer new targets for anti-cancer 
strategies (Sethi and Kang, 2011). It is still unclear how the cells from primary tumours 
obtain metastatic features. A linear hypothesis suggests that primary tumour cells go 
through several rounds of mutations until they obtain necessary metastatic features 
(Cairns, 1975). Interestingly, only a small subset of the heterogenic primary tumour 
cells becomes metastatic. On the other hand, the parallel model implies that separation 
and migration to the secondary hearth of cells originating from the primary tumour 
occurs at early stages of cancer development, followed by independent accumulation of 
mutations and metastasis (Klein, 2009). The linear hypothesis was supported by several 
genomic studies that clearly have shown that metastatic cells arise as a subset of 
primary tumour cells, separated at a late stage of tumourigenesis (Ding et al., 2010; 
Yachida et al., 2010). However, a genomic pattern has been described that defines the 
predisposition of a fraction of the cells to form metastasis (Perou et al., 2000). Such 
pattern suggests that there is a complex network of signal interactions that is crucial for 
metastasis development. Therefore, understanding and targeting the crucial nodes of 
such networks can be the strategy of treating metastatic tumours.  
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2 P53 AS AN ANTI-CANCER TARGET 
Nearly all late stage tumours have abrogated p53 function. Given the importance 
of p53 in tumour suppression and its cross-talk with numerous signalling pathways 
involved in carcinogenesis, pharmacological reactivation of p53 can be an important 
strategy to combat cancer. Studies in several mouse models addressed the question 
whether reinstatement of p53 can eliminate already established tumours and showed 
that the restoration of p53 activity in tumour cells leads to regression of tumours 
(Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007). On the other hand, most 
recent studies using mouse model of non-small-cell lung cancer (NSCLC) 
characterized by aberrant expression of mutant K-Ras oncogene, showed that the 
efficacy of p53 restoration greatly depends on level of K-Ras expression (Feldser et 
al., 2010; Junttila et al., 2010). p53 reactivation in early stage cancers with relatively 
normal level of K-Ras did not affect tumour growth. In contrast, restoration of p53 in 
more advanced adenocarcinomas resulted in significant tumour regression, via 
induction of cell-cycle arrest and apoptosis (Berns, 2010). Thus, restoration of p53 
activity might be a good anti-cancer therapeutic strategy for late stage tumours, rather 
than for the prevention of tumour formation. 
There are several known mechanisms of p53 deregulation in tumour cells. Nearly 
half of all tumours carry mutant p53 that is transcriptional inactive. As it was described 
earlier, most of these mutations occur in DNA binding domain with six hot spots at 
codons 175, 245, 248, 249, 273 and 282. As a result of mutations, DNA binding 
activity of mutant p53 towards its consensus motif is abrogated resulting in the loss of 
transcriptional function of p53 (Bullock et al., 2000; Epstein et al., 1998). 
In the remaining 50% of the tumours TP53 gene stays intact, while p53 activity is 
impaired, resulting in abrogated tumour suppressor function and enhanced formation of 
tumours. Such abrogation of p53 activity happens mainly due to the increased levels 
and/or activity of p53 negative regulators HDM2 and HDMX (Danovi et al., 2004; 
Momand et al., 1992; Riemenschneider et al., 1999). Enhanced activity of HDM2 
occurs often via several mechanisms. Thus, gene deletion or promoter 
hypermethylation of the HDM2 inhibitor p14ARF elevates HDM2 level (Esteller et al., 
2001; Sherr and Weber, 2000). In addition, overexpression of several p14ARF 
repressors including Bmi-1, Tbx-2 and TWIST results in HDM2 activation (Anim et 
al., 2005; Jacobs et al., 1999). On the other hand, overexpression of HDM2 in many 
tumours bearing wild-type p53 is achieved by HDM2 gene amplification, increased 
transcription and enhanced translation (Momand et al., 1998). 
Although the function of p53 is inactivated in the majority of tumours, the p53 
protein is still expressed, making it possible to design strategies to “revive” the dormant 
tumour suppressor. 
 
2.1 PHARMACOLOGICAL REACTIVATION OF WILD-TYPE P53 
One of the most common ways to induce wild-type p53, which has been already 
applied for many decades, is to use chemotherapeutic drugs. It is known that 
chemotherapeutic drugs in many cases act as DNA damaging agents that stabilize p53 
and induce p53-mediated cell cycle arrest or apoptosis. Notably, inactivation of p53 in 
several types of cancer cells makes them resistant to chemotherapy. However, 
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reintroduction of wild-type p53 to p53-null cancer cells recover their sensitivity to 
chemotherapeutic drugs (Wallace-Brodeur and Lowe, 1999). 
While chemotherapy is efficient and widely used strategy to treat cancer and to 
activate p53, it is not specific for p53 and produce the severe side effects in patients. 
This makes the search for non-genotoxic p53 activators a very important line of 
research. Already more then ten years ago researchers began to design more specific 
means of p53 activation. 
The molecular mechanisms of p53 regulation in cancer cells mentioned above 
suggest that inhibition of p53-HDM2/HDMX interaction might me an efficient way to 
fight cancer (Brown et al., 2011). While several promising chemical compounds that 
prevent inactivation of p53 by HDM2/HDMX have been identified in the last few 
years, it is still not completely clear whether they can be good drugs. Thus, mouse 
model studies showed that negative regulation of p53 by HDM2 or HDMX is essential 
for survival of mouse embryos (Jones et al., 1995; Montes de Oca Luna et al., 1995; 
Parant et al., 2001). At the same time a reasonable balance between p53 and its 
negative regulators is sufficient to induce mild level of p53 and therefore apoptosis in 
tumour cells without detectable side effects in normal tissues (Mendrysa et al., 2006). 
Milder effects of p53 restoration in HDMX-null in comparison to HDM2-null mice 
suggests that inhibition of HDMX might be a better therapeutic strategy for reactivating 
p53 (Garcia et al., 2011). 
Up to date a number of small molecules that target the p53-HDM2 interaction 
have been found, including Nutlin-3a, Benzodiazepine, RITA, MI-219, SAH-p53 
(Bernal et al., 2007; Ding et al., 2006; Garcia-Echeverria et al., 2000; Grasberger et al., 
2005; Issaeva et al., 2004; Popowicz et al., 2010; Vassilev et al., 2004), while WK298 
inhibits both HDM2 and HDMX interaction with p53 (Popowicz et al., 2010). There 
are two other specific inhibitors of HDMX/p53 interaction: SJ-172550 and a stapled 
p53 helix SAH-p53-8 (Bernal et al., 2010; Reed et al., 2010).  
Apart of targeting interaction of p53 with HDM2/HDMX, there is a possibility to 
target upstream regulators of p53-HDM2 interaction. For example, tenovins which 
inhibit protein-deacetylating activities of SirT1 and SirT2 of the sirtuin family stabilize 
of p53 via promoting its acetylation, thus preventing p53 ubiquitination by HDM2. 
This is followed by activation of p53 target genes (Lain et al., 2008). 
 Different mechanisms of wild-type p53 activation by chemotherapeutic drug 
5-FU and small molecules as the Nutlin-3a and RITA will be discussed in detail below. 
 
2.1.1 5-FU 
The chemotherapeutic drug 5-FU (5-fluorouracil) has been widely used for 
almost forty years for treatment of several types of cancers, including gastrointestinal, 
lung, breast and colon cancer. Despite of its efficient use, the mechanism of 5-FU is not 
completely clear yet. While the first metabolite of 5-FU, 5-fluorouridine 5’-
triphosphate (5-FUTP), might be incorporated into RNA, the second, 5-fluoro-2’-
deoxyuridine 5’-monophosphate (5-FdUMP), is a known inhibitor of thymidylate 
synthase (Parker and Cheng, 1990). As a consequence of such inhibition cells are 
arrested in S phase, followed by p53 activation. p53 activated upon 5-FU treatment 
induces its target genes and consequently cell growth and apoptosis (Nabeya et al., 
1995; Pickard et al., 1995). While 5-FU is not a direct inducer of p53 transcriptional 
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activity and can even kill p53-null cells, the presence of p53 is beneficial for 5-FU 
action (Osaki et al., 1997). 
 
2.1.2 Nutlins 
Nutlins are a class of small molecules that inhibit p53-HDM2 interaction via 
direct binding to the p53-binding pocket of HDM2 (Vassilev et al., 2004). Nutlins were 
identified in an in vitro biochemical screen of a library of synthetic compounds. 
Nutlin-1, Nutlin-2 and Nutlin-3 are the analogs of the original compound which are 
more potent inhibitors of p53-HDM2 interaction. While first two molecules exist as 
racemic mixtures, Nutlin-3a is an active enantiomer and has the lowest IC50 for the 
disruption of p53-HDM2 complex. The disruption of the p53-HDM2 interaction by 
Nutlins has been shown in biophysical experiments using NMR (D'Silva et al., 2005). 
Furthemore, Nutlin-3a is able to induce p53 activity and growth suppression in vivo and 
in vitro (Vassilev et al., 2004). Interestingly, in multiple tumour-derived cell lines 
Nutlin-3a preferentially induces p53 target genes involved in cell cycle arrest which 
correlates with reduced ability of cells to undergo p53-dependent apoptosis (Tovar et 
al., 2006). Notably, Nutlin-3a also affects proliferation of normal cells, inducing 
reversible cell cycle arrest. This phenomenon lead to the idea of “cyclotherapy”, i.e., to 
use Nutlin-3a pre-treatment as a protection of normal cells from the side effects caused 
by chemotherapeutic treatment or targeted drugs that would usually affect normal cells, 
such as the Aurora kinase A inhibitor VX-680. On the other hand, actively proliferating 
tumour cells with mutant p53 will be not arrested by Nutlin-3a and therefore will be 
sensitive to chemotherapy or VX-680 (Cheok et al., 2010). 
 
2.1.3 RITA 
RITA (reactivation of p53 and induction of tumour cell apoptosis) is a small 
molecule, which has been discovered via screening of a National Cancer Institute (NCI) 
library of compounds using a cell-based assay searching for the compounds which 
suppress the growth of the HCT116 cells expressing wild-type p53, but not that of the 
isogenic p53-null cell line (Issaeva et al., 2004). RITA binds p53 and prevents the 
interaction between p53 and HDM2 in vitro and in vivo (Issaeva et al., 2004).  
RITA activates apoptosis in tumour cell lines of different origin, including colon, 
lung, skin, and breast carcinomas, osteosarcoma as well as lymphomas. In contrast, it 
does not affect the growth of non-transformed fibroblasts or epithelial cells (Issaeva et 
al., 2004). Furthermore, RITA suppressed the growth of HCT116 xenografts in mice, 
without noticeable side effects (Issaeva et al., 2004). Early studies attributed the growth 
inhibitory effects of RITA to its ability to cross-link DNA-DNA and DNA-protein 
complexes in human renal cancer cells, which depends on the cell uptake and 
metabolism of the compound (Nieves-Neira et al., 1999; Rivera et al., 1999). However, 
several studies have shown that RITA-mediated effects on growth suppression of cells 
are dependent on presence of p53 (Ahmed et al., 2011; Issaeva et al., 2004; Kazemi et 
al., 2011; Nahi et al., 2008). Indeed, RITA-induced DNA damage signalling occurs 
only in p53-positive cell lines (Yang et al., 2009a; Yang et al., 2009b).  
Interestingly, in contrast to Nutlin-3a, RITA stimulates p21Waf1 degradation that 
shifts the balance towards induction of apoptosis rather then cell cycle arrest upon p53 
activation (Enge et al., 2009). 
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Recent studies also have shown new feature of RITA to induce the presence of 
ULBP1 and ULBP2 ligands for NK cell on the surface. These findings suggest a new 
anti-cancer strategy: to combine p53 activation with NK-based therapy in the wild-type 
p53 carrying tumours (Li et al., 2011; Textor et al., 2011). 
 
2.2 PHARMACOLOGICAL REACTIVATION OF MUTANT P53 
Since nearly fifty percent of all tumours carry mutant p53, several studies have 
been performed to identify small molecules that are able to reactivate mutant p53 and 
therefore selectively kill cancer cells expressing mutant p53. CDB3, CP31398, 
PRIMA-1MET, PhiKan083 and SCH529074 have been found to restore the function of 
mutant p53 (Boeckler et al., 2008; Bykov et al., 2002; Demma et al., 2010; Foster et al., 
1999; Friedler et al., 2002). Since different point mutations of p53 produce a common 
effect, i.e., partial unfolding of p53, most of the molecules mentioned above are active 
towards different mutants. The exception is PhiKan083, specifically designed to target 
the Y220C mutation. These compounds are currently in different stages of 
development. The first clinical trial for PRIMA-1MET/APR-246 has been completed in 
2011; hopefully a Phase II trial of APR-246 will be launched in 2012. 
 
2.3 P53 GENE THERAPY AND ONYX-015 
Another strategy to reactivate mutant p53 is to replace mutant gene with the active 
wild-type copy. Two different virus systems are used to achieve this. 
The first strategy to integrate the TP53 gene into the genome is to use retroviruses. 
Several studies shows that retrovirus-mediated incorporation of wild-type p53 in lung 
cancer cell lines as well as in xenografts inhibited the growth of tumour cells (Cai et al., 
1993; Fujiwara et al., 1993; Runnebaum et al., 1995). 
Another strategy of gene delivery is based on adenovirus. Advexin and Gendicine 
are two drugs that demonstrate growth suppression activity in tumours and have been 
tested in phase I, II and III clinical trials (Yang et al., 2010).  
In contrast to TP53 gene therapy, adenovirus-based ONYX-015 which has deleted 
p53 inhibitor E1B does not deliver functional p53, but selectively replicates in cells 
with dysfunctional p53, consequently lysing them leading to the regression of tumours 
(Nemunaitis et al., 2007). 
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3 AIMS OF THE THESIS 
This thesis is focused on the studies of the molecular mechanisms of 
pharmacological reactivation of p53. In particular, we investigated the transcriptional 
activity of reactivated p53 and its role in induction of apoptosis. Deeper understanding 
of these issues will help to more efficiently apply the pharmacological reactivation of 
p53 as a therapeutic strategy to cure cancer. 
 
Specific aims: 
 
• To study genome-wide occupancy of p53 at its target promoters upon different 
means of pharmacological activation of p53 and to identify the new 
transcriptional cofactors of p53 (Paper I). 
 
• To investigate the impact of transcriptional modulation by p53 of different sets 
of genes on RITA-mediated apoptosis in tumour cells (Paper II). 
 
• To establish the impact of p53 reactivated by RITA on the aerobic glycolysis 
and genes that control this process (Paper III). 
 
• To investigate the impact of pharmacologically reactivated p53 on its major 
negative regulators HDMX and Wip1 (Paper IV). 
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4 RESULTS AND DISCUSSION 
Four papers that are discussed in this thesis focuse on different aspects of the 
pharmacological reactivation of p53, from phenotype to transcriptional regulation of 
single genes. 
 
Paper I. 
 
Insights into p53 Transcriptional Function via Genome-Wide Chromatin Occupancy and 
Gene Expression Analysis 
 
Fedor Nikulenkov, Clemens Spinnler, Claudia Tonelli, Mikko Turunen, Hai Li, Teemu 
Kivioja, Alexander Kel, Jussi Taipale and Galina Selivanova 
 
 The starting point for this study was the finding that the different mechanisms of 
pharmacological activation of p53, i.e. by Nutlin-3a and RITA, induce very different 
transcriptional programs (Enge et al., 2009). More, Nutlin-3a and RITA treatment lead 
to diverse phenotypic responses in the same cell lines: cell cycle arrest or apoptosis, 
respectively. Thus we addressed a question, whether it occurs due to the differential 
binding of p53 to its target genes upon different stimuli, leading to the differential gene 
expression patterns or whether p53 binds to the same sites irrespective of the type of its 
induction, whereas the presence of cofactors decides whether the gene will be induced 
or not. Due to the technological revolution in biology, in particularly, the development 
of high-throughput sequencing technology it becomes possible to study global genome 
occupancy of transcription factors and answer such questions. 
Thus, we treated breast cancer MCF7 cells with three different pharmacological 
activators of p53 (5-FU, Nutlin-3a and RITA) and analysed the genome-wide p53 
occupancy in these cells using ChIP-seq method. Surprisingly, we found that there is a 
“default p53 program”, comprising a set of binding sites that is occupied by p53 
independently on the type of activation stimuli. Furthermore, using the p53 scan 
algorithm we showed that these sites are enriched for the p53 motif. However, there 
was also a small number of sites bound by p53 which were unique for different 
treatments. While these sites were not significantly enriched for the p53 consensus 
motif, we can not exclude the possibility that these sites, different from the “default p53 
program” are important for the differential phenotypic responses.  
While previous studies have shown that in most cases p53 binds to DNA in the 
vicinity of transcription starting sites (TSS) we found that only 34% of the “default p53 
program” peaks were located within 10kbp from TSS. The relatively large number of 
peaks identified to be distant from TSS suggests that either a number of the p53 target 
genes are regulated by p53 via DNA looping or at least some of these p53-DNA 
binding events are irrelevant for the regulation of transcription by p53. 
Combination of the analysis of global gene expression changes upon Nutlin-3a 
treatment and genome-wide chromatin occupancy revealed 280 novel p53 target genes. 
Among them the transcription of 214 genes was induced and 66 genes were repressed. 
Interestingly, in contrast to induced genes only a small portion of the repressed genes 
shared p53 consensus motif, suggesting that the mechanism of repression occurs either 
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through indirect p53 binding or through motifs which are significantly different from 
the p53 consensus. 
 We have chosen AURKA (repressed) and SERTAD1 (induced) as the most 
interesting new targets of p53 and further validated them using several methods. 
AURKA encodes Aurora A kinase that is unfavourable prognostic marker in cancer and 
used as a target for anti-cancer therapies. Our studies suggest that STAT3 can be an 
important cofactor antagonizing p53-mediated repression of number of genes, 
including AURKA.  
To elucidate the clinical importance of the identified p53 target genes we 
performed hierarchical clustering of the expression levels of p53 target genes in 265 
breast tumour patient samples. We found a significant correlation between the 
expression of a number of p53 target genes that we identified, and the status of p53, 
grade of the tumours and long-term survival prognosis. These data suggested that 
newly identified p53 targets might be used as clinical prognostic markers in breast 
tumour patients.  
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Paper II. 
 
Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient 
apoptosis. 
 
Grinkevich VV, Nikulenkov F*, Shi Y*, Enge M, Bao W, Maljukova A, Gluch A, Kel A, 
Sangfelt O, Selivanova G. 
* equal contribution 
 
 The analysis of gene expression microarrays in breast tumour MCF7 cells as well 
as in colon cancer HCT116 cells revealed a significant decrease in transcription of a set 
of oncogenes (IGF1R, PIK3CA, PIK3CB, MYC, EIF4E, BCL2, MAP4, MCL1) upon 
RITA treatment in comparison to untreated samples, validated further by qPCR. 
Additionally, the repression of these genes was totally p53-dependent, as we did not 
observe any changes in expression upon 1 µM RITA treatment in several p53-null cell 
lines (HCT116 p53-/-, H1299, SAOS2). Importantly, RITA did not affect the 
expression of these genes in untransformed cells.  
Our data also showed that p53 activation upon RITA resulted not only in dramatic 
transcriptional changes. Apart from the transcriptional repression of anti-apoptotic 
proteins Bcl-2 and Mcl-1, as well as several proteins involved in the IGF-1R/PI3K/Akt 
pathway, inhibition of a number of oncogenes occurs on the level of translation and 
protein stability. The activity of several proteins involved in the IGF-1R/PI3K/Akt 
pathway was abrogated, that led to inhibition of mTOR, EIF4E and consequently c-
Myc translation. The stability of already synthesized proteins c-Myc, β-catenin and 
Cyclin E was also decreased due to the activation of GSK3β and the E3 ligase FBXW7 
(hCdc4), which play important roles in proteasomal degradation of oncoproteins. Thus, 
we showed that pharmacologically activated p53, apart from triggering the expression 
of pro-apoptotic proteins, also suppresses the survival factors via several mechanisms. 
Surprisingly, we found that the inhibition of oncogenic proteins was dependent on 
the dose of RITA, while induction of pro-apoptotic factors was observed irrespective of 
a dose. At the same time, the level of p53 induction was comparable upon 0.1 µM and 
1 µM RITA treatment. Notably, the absence of oncogene inhibition at lower dose 
(0.1 µM) of RITA in tumour cells correlated with weak apoptosis induction in 
comparison to that induced by 1uM RITA. Further investigation of the difference 
between these two doses revealed significantly higher levels of p53 on chromatin upon 
1 µM RITA. Moreover, we found that HDM2 bound to p53 on chromatin might play a 
key role in the observed dose-dependent differences in regulation of oncogenes. Indeed, 
investigation of the promoter occupancy by p53-HDM2 complexes showed that 
treatment with 0.1 µM RITA increased the p53/HDM2 ratio on p53-induced gene 
(CDKN1A) promoters, but not on the repressed (MCL1), while 1 µM RITA elevated 
p53/HDM2 ratio on both promoters. Thus, we suggested that dose-dependent 
repression of oncogenes depends on the HDM2/p53 ratio on repressed promoters. 
Finally, we addressed the impact of the inhibition of pro-survival genes on induction of 
apoptosis upon high dose of RITA. We showed that pharmacological inhibition 
(LY294002 treatment) of the IGF-1R/PI3K/Akt pathway or depletion of the pro-
survival Mcl-1 factor in combination with low dose of RITA is sufficient to induce 
massive apoptosis in tumour cells. Thus, we concluded that the repression of pro-
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survival and pro-proliferative factors is essential for the robust induction of p53-
mediated apoptosis in tumour cells. 
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Paper III. 
 
Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: 
targeting Warburg effect to fight cancer. 
 
Joanna Zawacka-Pankau*, Vera V. Grinkevich*, Sabine Hüenten§, Fedor Nikulenkov§, Angela 
Gluch, Hai Li, Martin Enge, Alexander Kel, Galina Selivanova 
*, § equal contribution 
 
The third study was a logical continuation of second paper, where we have shown 
an important role of p53-mediated inhibition of oncogenes in induction of apoptosis in 
tumour cells.  
In this study we explored whether pharmacologically activated p53 is able to 
inhibit aerobic glycolysis, the essential source of energy in tumour cells. Indeed, 
metabolic measurement of acidification status that reflects the lactate export (final 
product of glycolysis) showed that 1 µM RITA treatment led to p53-mediated 
inhibition of cell metabolism. Interestingly, glycolytic inhibition was not a consequence 
of apoptosis and was detected only in p53-positive cells. 
Further microarray analysis of gene expression in MCF7 and HCT116 cancer cells 
revealed that a set of key metabolic genes, like SLC2A1, HKII, PFKB3, PFK, PGM3, 
LDHA, PDK1 as well as factors regulating metabolic genes (MYC, HIF1A, PI3CA and 
PI3CB) were substantially repressed upon 1 µM RITA treatment. Several genes were 
selected for further investigation and validation by qPCR and western blot. Thus, we 
showed that SLC2A1, HKII, PFKFB3, SLC2A12, PDK1 and HIF1A genes were 
repressed in a p53-dependent manner in both tumour cells and xenografts in vivo, 
although the observed downregulation of some genes was less pronounced in vivo. 
Notably, the inhibition of HIF1A and HKII expression was accompanied by a strong 
depletion of HIF1α and HK2 protein levels in several tumour cells (U2OS, HCT116, 
MCF7). 
Interestingly, we found that some of these metabolic genes (SLC2A1, HIF1A, 
SLC2A12) might be direct transcriptional targets of p53, in addition to already known 
C12orf5 and MYC.  
Since many tumours face hypoxic environment and express a high level of HIF1α, 
we addressed the impact of HIF1α inhibition on the expression of metabolic genes 
under hypoxia and normoxia. Our data clearly demonstrated that p53-mediated 
repression of HIF1α contributes to the ablation of metabolic genes in hypoxic, but not 
normoxic conditions in tumour cells.  
Additionally, bioinformatics promoter analysis of studied metabolic genes revealed 
several other cofactors that might have binding sites in promoters of these genes and 
therefore regulate their transcription. Key node analysis of gene expression data 
revealed that SP1 is tightly linked with p53. Thus, we decided to study impact of SP1on 
p53-mediated transcriptional regulation of metabolic genes and found that the depletion 
of SP1 in MCF7 cells partially, but significantly protect some metabolic genes from 
repression upon RITA treatment. These data implies that SP1 cooperates with p53 in 
transcriptional repression of metabolic genes. Furthermore, observed protection of 
metabolic genes from p53-mediated repression in SP1-depleted cells correlated with 
attenuated cell growth suppression. 
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On other hand, depletion of HK2 in combination with 0.1 µM RITA significantly 
increased apoptosis in MCF7 cells, suggesting that the repression of at least some 
metabolic genes contributes to apoptosis caused by RITA in tumour cells. 
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Paper IV. 
 
Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis 
induction via activation of ATM and inhibition of HdmX 
 
C. Spinnler*, E. Hedström*, H Li, J de Lange, F Nikulenkov, AFAS Teunisse, M Verlaan-de 
Vries, V Grinkevich, A Jochemsen and G Selivanova 
* equal contribution 
 
In the fourth study we investigated the mechanisms and impact of downregulation 
of p53 negative regulator HDMX upon RITA treatment in tumour cells. HDMX is 
known to be overexpressed in many tumours, which causes abrogation of p53 function 
(Ramos et al., 2001; Riemenschneider et al., 1999). Therefore, it is particularly 
important to investigate the molecular mechanisms of HDMX downregulation which 
we observed upon RITA treatment. 
In this study we found that RITA induced a rapid ablation of HDMX protein level 
in most tumour cell lines bearing wild-type p53 (MCF7, U2OS, HCT116, HT1080, 
LIM1215, A549, A498) as well as in xenografts. In contrast, another pharmacological 
inducer of p53, Nutlin-3a did not affect the HDMX level. Depletion of HDMX upon 
RITA treatment was totally p53-dependent and not observed in normal cell lines. 
Interestingly, downregulation of HDMX correlated with RITA-induced apoptosis. All 
cell lines that had decreased HDMX level were sensitive to RITA treatment, while 
RKO and SJSA tumour cells, which did not respond to RITA, did not show any 
changes in HDMX. Additionally, the depletion of HDMX in HCT116 cells promoted 
apoptosis induced by RITA. 
Further, we addressed the mechanisms underlying the downregulation of HDMX 
by assessing the changes in half-life of HDMX upon RITA treatment. We showed that 
the stability of HDMX was drastically decreased due to proteasome degradation. Since 
HDM2 is major negative regulator of HDMX stability we checked whether RITA-
mediated downregulation was caused by HDM2. Depletion of HDM2 in HCT116 cells 
resulted in increased HDMX level in untreated cells, but did not prevent from RITA-
induced downregulation of HDMX. Instead, we found that ATM played an essential 
role in HDMX degradation by RITA, since the depletion of ATM partially protected 
HDMX from downregulation. ATM kinase is a transducer of DNA damage signalling 
which phosporylates several substrates including HDMX. In line with previously 
published data, we showed that RITA activated ATM, which also correlated with the 
accumulation of HDMX phosphorylated at ATM-dependent sites S367 and S403. 
Further, we demonstrated that phosphorylation of HDMX on these sites is crucial for 
its proteasomal degradation since RITA did not affect the half-life of non-
phosphorylatable triple mutant HDMX carrying S342A, S367A and S403A 
substitutions. 
Next, we found that Wip1 phosphatase which negatively regulates the activity of 
ATM through its dephosphorylation, was downregulated in p53-dependent manner on 
transcriptional and protein levels, as accessed by qPCR and western blotting. We 
further showed that the depletion of Wip1 led to downregulaton of HDMX, which was 
even more pronounced upon RITA treatment in HCT116 cells. Additionally we 
showed that the depletion of Wip1 promoted growth suppression of tumour cells upon 
RITA treatment as well as upon Nutlin3a. 
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Thus, this study revealed that RITA inhibits Wip1 and HDMX oncogenes, 
resulting in disruption of the p53/Wip1/HDMX negative feedback loop. Such 
pharmacologically mediated block of p53 inhibitors might be essential for the induction 
of robust growth suppression, leading to regression of tumours. 
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5 CONCLUSIONS AND REMARKS 
My way to the p53 field started seven years ago when all students at our 
department had to choose a laboratory for their master thesis. For most of us it was a 
very hard decision to select the field they wanted to work in, while I knew exactly that 
it should be tumour biology. Both grandparents on my mother’s side died from cancer 
when I was very small, which kept alive in my mind how ruthless, painful and in many 
case hopeless this disease can be. Being idealistic, I dreamt about discovering the 
treatments that would help mankind to win the battle against cancer. Looking back now 
I understand how naive my view on cancer used to be. At the same time I appreciate 
now how challenging it is to unravel the mechanisms of tumourigenesis.  
Although today many molecules and signalling pathways that can drive 
tumourigenesis are discovered, the selection of the appropriate strategy to combat 
cancer remains difficult. This is especially true for cancer, as each tumour is probably 
as individual as each patient itself and, moreover, consists of a heterogenic population 
of cells with various abnormalities. On the other hand, the central tumour suppressive 
role of p53 in cells and it’s deregulation observed in nearly all tumour cells make p53 a 
very promising target for anti-cancer therapy. Indeed, restoration of p53 function in 
mice with established tumours entails growth inhibition and tumour regression, 
although the observed effects depend on the tumour grade (Martins et al., 2006; 
Ventura et al., 2007; Xue et al., 2007). Several approaches are used to restore p53 in 
cells, while the most common is pharmacological reactivation. Thus, many 
chemotherapeutic drugs are the first wild-type p53 reactivators, e.g. 5-FU. In our lab 
several small molecules were discovered that suppress tumour growth in a p53-
dependent manner, including MITA and RITA (Hedstrom et al., 2009b; Issaeva et al., 
2004). Both RITA and MITA induce apoptosis in different types of tumour cell lines, 
such as lung, colon and breast carcinomas. In the original paper RITA was shown to 
bind the p53 N-terminus, thus preventing formation of p53-HDM2 complexes and, 
therefore, increasing stability and activity of p53. On the other hand, Nutlins activate 
p53 by occupying the p53-binding pocket in HDM2 (Vassilev et al., 2004), resulting in 
induction of cell-cycle arrest and to less extent apoptosis.  
The work presented in this thesis provides insight into various mechanisms playing 
important roles in growth-inhibitory effects of pharmacologically reactivated p53.  
Treatment with various reactivating compounds results in accumulation of p53 
and induction of its transcriptional program, which differs depending on the mechanism 
of p53 activation. p53 regulates gene transcription via binding to REs in the vicinity to 
TSS and therefore promotes initiation and elongation of transcription. Thus, in the first 
paper we addressed the question how different pharmacological activators of p53, such 
as 5-FU, RITA and Nutlin-3a, influence p53’s genome-wide DNA binding profile and 
how this leads to various cellular outcomes. In agreement with previous studies 
(Shaked et al., 2008; Smeenk et al., 2011), we showed that p53 occupies core binding 
sites irrespectively to the type of p53 activation and cell fate. Thus, we speculate that 
post-translational modifications or/and interaction with cofactors might redirect 
transcriptional activity of DNA-bound p53 from promotion of cell cycle arrest to 
apoptosis. Indeed, S46 phosphorylation of p53 bound to DNA results in predominant 
activation of pro-apoptotic genes and consequently apoptosis (Smeenk et al., 2011). In 
addition, we showed that many of the p53 binding sites are found at significant 
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distances from TSS, raising the questions whether these sites play any role in regulation 
of the transcription or cell fate. We also identified 280 new potential p53 targets, 
including AURKA that might serve as possible prognostic markers. Previous 
bioinformatic studies suggested that KLF/PAX4, SP1 and NFκB transcription factors 
coregulate p53 target genes (Smeenk et al., 2008). In addition to these factors, our 
analysis revealed STAT3 as a novel coregulator of p53 target genes that, in particular, 
antagonize p53 repressive activity on the AURKA promoter. 
We investigated various aspects of p53 activity upon RITA treatment that 
contribute to apoptosis. A global analysis of transcriptional changes caused by RITA 
demonstrates that expression of more then two thousand genes is affected in a p53-
dependent manner (Enge et al., 2009). Furthermore, pathway analysis reveals that pro-
apoptotic genes are among the most efficiently induced. Moreover, in paper II we 
showed that transcription of a number of oncogenic and pro-survival factors, such as 
IGF1R, PIK3CA, PIK3CB, MYC, EIF4E, BCL2, MAP4, MCL1, was repressed. In 
addition, the pro-survival protein Mcl-1 and c-Myc oncogene were inhibited on 
multiple levels. For both, the block of the IGF-1R/PI3K/Akt pathway was affecting 
protein degradation and translation of these proteins. In conclusion, we showed that the 
observed repression of oncogenes significantly contributes to apoptosis and represents 
an additional mechanism that increases the robustness of p53-mediated tumour 
suppression. Interestingly, we observed differential regulation of induced pro-apoptotic 
genes and repressed oncogenes, which depends on the binding of HDM2 to the target 
gene promoters. In addition, a study by Enge et al. demonstrates that HDM2 inhibits 
p21Waf1 protein level. Such depletion plays an important role in RITA-mediated growth 
suppression by tilting the balance between growth arrest and apoptosis (Enge et al., 
2009).  
On other hand, in paper IV we showed that RITA downregulates mRNA and 
protein level of another important HDM2-related inhibitor of p53, namely HDMX. The 
observed depletion of HDMX levels was mediated by DNA damage induced ATM 
kinase, whose activity was in turn elevated due to p53-mediated downregulation of 
Wip1 phosphatase. Inactivation of HDMX and Wip1 further extend the complexity of 
RITA action and its robust ability to induce apoptosis in tumour cells.  
Previous study from our group by Hedström et al. shows that, in addition to 
p53, RITA also binds theoredoxin reductase 1 (TrxR1) and induces pro-oxidant genes 
as well as ROS levels in a p53-dependent manner (Hedstrom et al., 2009a). In addition, 
paper III shows that RITA represses the anti-oxidant gene C12orf5. Furthermore, we 
investigated the impact of RITA on ATP production from aerobic glycolysis in tumour 
cells and surprisingly found that a set of key metabolic genes was repressed. This 
occurred both on mRNA and protein level in a p53-dependent manner, leading to 
inhibition of cell metabolism. Interestingly, we found that transcription of SLC2A1, 
HIF1A and SLC2A12 might be directly repressed by p53. Furthermore, we identified 
the SP1 transcription factor to be crucial for the p53-mediated repression of a number 
of metabolic genes and induction of apoptosis. 
In conclusion, we identified several p53-mediated effects of RITA that impinge 
on several crucial factors important for tumour cell survival. These broad effects reveal 
RITA as potent anti-cancer compound. Taking in account that tumours are very 
heterogeneous and that several subpopulations of cells with various aberrations are 
present within the same tumour, the ability of pharmacologically activated p53 to affect 
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multiple signalling pathways might be favourable as it allows to induce apoptosis in 
many tumour cells, regardless of what mutations they carry. 
Furthermore, we used the properties of p53 activating molecules to address 
general questions concerning the biology of p53-mediated transcription and regulation 
of cell fate decision. Along with the newly identified target genes, these data may 
contribute to the deeper understanding of tumour biology and inspire the development 
of future cancer therapies. 
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